
    
      The study will be conducted in China to provide safety and efficacy data from this region. A
      Safety Run-in will be conducted to confirm the safety of the recommended Phase 2 dose (RP2D),
      80 mg once daily, in a Asian population. PK samplings at Cycle 1, Day 1 will be taken.
    
  